Minireviews
Copyright ©The Author(s) 2021.
World J Gastroenterol. Oct 7, 2021; 27(37): 6231-6247
Published online Oct 7, 2021. doi: 10.3748/wjg.v27.i37.6231
Table 1 Association between various thresholds for serum drug concentrations and clinical outcomes
Drug
Serum drug level
Clinical outcome
Infliximab (IFX)
IFX< 2 μg/mL for CD/UC at week 14Increased incidence of IFX antibodies[52]
IFX> 2.1 μg/mL at week 14 in UCAssociated with mucosal healing[53]
IFX≥ 3 μg/mL during maintenanceClinical remission[48]
IFX> 3 μg/mL at week 14 or 22 in CDSustained response[54]
IFX3-7 μg/mL during maintenanceRemission[16]
IFX≥ 7 μg/mL during maintenanceMucosal healing[48]
IFX< 7 μg/mL at week 14 in luminal CDAbsence of primary response[53]
IFX> 9.2 μg/mL at induction week 2 in CDFistula response at weeks 14 and 30[56]
IFX≥ 10 μg/mL at induction week 6Clinical response[48]
IFX> 15 μg/mL at week 6 in UCAssociated with mucosal healing[53]
IFX≥ 20 μg/mL at induction week 2Clinical response[48]
IFX≥ 22 μg/mL at week 6 in UCClinical response at week 8[55]
IFX≥ 25 μg/mL at induction week 2Mucosal healing[48]
Adalimumab (Ada.)
Ada.≥ 3 μg/mL during maintenanceClinical response[48]
Ada.≥ 5 μg/mL post induction (week 14)Clinical response[48]
Ada.≥ 7 μg/mL post induction (week 14)Mucosal healing[48]
Ada.≥ 8 μg/mL during maintenanceMucosal healing[48]
Ada.< 12 μg/mL at week 14 in luminal CDAbsence of primary response[53]
Ustekinumab (UST)
UST≥ 1 μg/mL during maintenanceClinical response[48]
UST≥ 3.5 μg/mL post induction (week 8)Clinical response[48]
UST≥ 4.5 μg/mL during maintenanceMucosal healing[48]
Vedolizumab (VDZ)
VDZ≥ 12 μg/mL during maintenanceClinical response[48]
VDZ≥ 14 μg/mL during maintenanceMucosal healing[48]
VDZ≥ 15 μg/mL post induction (week 14)Clinical response[48]
VDZ≥ 17 μg/mL post induction (week 14)Mucosal healing[48]
VDZ≥ 24 μg/mL at induction (week 6)Clinical response[48]
VDZ≥ 28 μg/mL at induction (week 2)Clinical response[48]